- Home
- MKZR vs KPRX Comparison
MKZR vs KPRX Comparison
Compare MKZR & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKZR | KPRX |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 8.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MKZR | KPRX |
|---|---|---|
| Price | $4.79 | $2.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 31.8K | ★ 37.8K |
| Earning Date | 02-11-2026 | 11-07-2025 |
| Dividend Yield | ★ 10.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,994,778.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.63 | N/A |
| 52 Week Low | $3.26 | $1.77 |
| 52 Week High | $31.80 | $4.18 |
Technical Indicators
Market Signals| Indicator | MKZR | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 45.27 |
| Support Level | $4.36 | $2.02 |
| Resistance Level | $4.79 | $2.32 |
| Average True Range (ATR) | 0.39 | 0.10 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 37.92 | 20.01 |
Price Performance
Historical ComparisonAbout MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate. It is a real estate investment manager who utilizes an approach to real estate securities, often seeing opportunities that others overlook. Based in Orinda, California, MacKenzie Capital Management has specialized in discounted real estate securities and asset management.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.